← Back to all trials
Recruiting
NCT07215312
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
Conditions: Diabetes Mellitus, Type 2
Sex: All
Ages: 18 Years – 70 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 100
Sponsor: Eli Lilly and Company
Location: Tucson Clinical Research Institute Tucson Arizona
Summary
The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.
Eligibility Criteria
Inclusion Criteria:
* Have type 2 diabetes
* Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening
* Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive
* Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)
Exclusion Criteria:
* Have type 1 diabetes
Source: ClinicalTrials.gov (NCT07215312). StuddyBuddy aggregates publicly available trial information.
